Network-1 Technologies, Inc. announced that ILiAD Biotechnologies, LLC reported the first-ever demonstration of protection against B. pertussis (whooping cough) colonization in a Phase 2b Human Challenge study of its BPZE1 vaccine. ILiAD announced that its BPZE1 intranasal pertussis vaccine has met the primary endpoint of protection against nasopharyngeal B. pertussis colonization (p=0.03) in the Phase 2b CHAMPION-1 Study. To date, Network-1 has invested an aggregate of $7,000,000 in ILiAD which represents approximately 6.8% of the outstanding units of ILiAD on a non-fully diluted basis.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.94 USD | +0.52% | -0.51% | -11.01% |
1st Jan change | Capi. | |
---|---|---|
-11.01% | 45.61M | |
+25.08% | 483M | |
+1.83% | 334M | |
-10.69% | 147M | |
+61.58% | 140M | |
-.--% | 139M | |
+142.88% | 95.63M | |
-2.80% | 73.01M | |
+57.43% | 53.28M |
- Stock Market
- Equities
- NTIP Stock
- News Network-1 Technologies, Inc.
- Network-1 Technologies, Inc. Reports First-Ever Demonstration of Protection Against B. Pertussis Colonization in Phase 2B Human Challenge Study of Bpzel Vaccine